RecruitingPhase 1Phase 2NCT07034053

Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Clofarabine Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study

Sponsor

Ekaterina Laukhtina

Enrollment

50 participants

Start Date

Oct 24, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Urothelial Carcinoma Metastatic Urothelial Cancer

Summary

This phase 1/2 study will evaluate the maximum tolerated dose, efficacy, and safety of clofarabine in patients with advanced or metastatic urothelial cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Clofarabine for people with advanced urothelial carcinoma and metastatic urothelial cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClofarabine

Patients receive i.v. clofarabine in a dose-escalation regimen

Locations(1)

Department of Urology, Medical University of Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07034053

Related Trials

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

NCT072417936 locations

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT0592923512 locations

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596170 locations

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973135 locations

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

NCT072219421 location